Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 + Sintilimab vs Sorafenib in First-line Advanced HCC
NCT04720716Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Feb 2021
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of IBI310 in hepatocellular carcinoma (HCC), sponsored by Innovent Biologics. Started Feb 2021; status: completed.
02
Drugs
IBI310
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04720716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720716.